At its Annual Meeting on July 7, 2026, Cellectar Biosciences stockholders approved an increase of 2,000,000 shares reserved for issuance under the 2021 Stock Incentive Plan. Stockholders also approved the exercise of warrants to purchase up to 39,618,078 shares of common stock under Nasdaq rules. Additionally, Andrew Gu and Douglas J. Swirsky were elected as Class III directors, and the appointment of Deloitte & Touche LLP as the independent auditor for fiscal year 2026 was ratified. The company is a biopharmaceutical company that develops targeted radiopharmaceuticals for cancer treatment.